Total debt declined to $9.7M in 2026Q2 with a debt-to-equity ratio of 0.07, but cash of $22.7M and an accumulated deficit of $758.7M indicate the capital structure is funded almost entirely by equity issuance.
ALX Oncology Holdings Inc. (ALXO) balance sheet — 8-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Total Current Assets | 152.87M | 50.73M | 134.35M | 188.66M | 270.97M | 367.02M | 435.99M | 9.81M | 10.21M |
| Cash & Short-Term Investments | 147.21M | 44.79M | 127.76M | 182.74M | 266.21M | 363.67M | 434.22M | 9.02M | 8.26M |
| Cash Only | 35.45M | 16.37M | 17.57M | 22.41M | 48.82M | 363.67M | 434.22M | 9.02M | 8.26M |
| Short-Term Investments | 111.75M | 28.42M | 110.19M | 160.33M | 217.38M | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 298K | 892K | 0 | 0 | 0 | 0 | 536K | 932K |
| Days Sales Outstanding | - | - | - | - | - | - | - | 40.79 | 164.58 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 5.66M | 5.64M | 5.7M | 5.92M | 4.76M | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 1.8M | 8.32M | 13.42M | 53.89M | 35.52M | 13.16M | 62K | 867K | 956K |
| Property, Plant & Equipment | 149K | 1.2M | 9.63M | 10.84M | 9.81M | 3.47M | 52K | 860K | 956K |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | 22.73x | 5.58x | 2.16x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 47.42M | 3.49M | 3.52M | 35.41M | 16.7M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.66M | 3.63M | 267K | 7.64M | 9.01M | 9.69M | 10K | 7K | 0 |
| Total Assets | 154.67M | 59.05M | 147.78M | 242.55M | 306.49M | 380.18M | 436.05M | 10.68M | 11.16M |
| Asset Turnover | 0.00x | - | - | - | - | - | 0.00x | 0.45x | 0.19x |
| Asset Growth % | 143.15% | -60.04% | -39.08% | -20.86% | -19.38% | -12.81% | 3984.43% | -4.37% | - |
| Total Current Liabilities | 19.02M | 24.55M | 18.5M | 36M | 28.32M | 15.29M | 6.2M | 4.98M | 1.87M |
| Accounts Payable | 3.99M | 4.91M | 4.5M | 8.59M | 8.07M | 3.76M | 4K | 3.75M | 697K |
| Days Payables Outstanding | 9.6K | - | - | - | - | - | 1.36 | 313.77 | 135.32 |
| Short-Term Debt | 0 | 5.22M | 435K | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 19.02M | 14.42M | 5.97M | 6.7M | 4.72M | 3.53M | 2.13M | 1.06M | 369K |
| Current Ratio | 8.04x | 2.07x | 7.26x | 5.24x | 9.57x | 24.00x | 70.28x | 1.97x | 5.45x |
| Quick Ratio | 8.04x | 2.07x | 7.26x | 5.24x | 9.57x | 24.00x | 70.28x | 1.97x | 5.45x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 9.8M | 8.51M | 15.66M | 16.84M | 14.7M | 1.84M | 5K | 5.97M | 136K |
| Long-Term Debt | 0 | 0 | 9.47M | 9.64M | 9.39M | 0 | 0 | 5.42M | 0 |
| Capital Lease Obligations | 0 | 0 | 5.16M | 5.98M | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 9.8M | 8.51M | 1.03M | 1.22M | 5.31M | 1.84M | 5K | 412K | 0 |
| Total Liabilities | 28.82M | 33.06M | 34.16M | 52.84M | 43.02M | 17.13M | 6.21M | 10.95M | 2.01M |
| Total Debt | 0 | 5.22M | 16.98M | 17.2M | 10.43M | 742K | 0 | 5.42M | 0 |
| Net Debt | -35.45M | -11.16M | -589K | -5.21M | -38.39M | -362.93M | -434.22M | -3.6M | -8.26M |
| Debt / Equity | 0.00x | 0.20x | 0.15x | 0.09x | 0.04x | 0.00x | - | - | - |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.43x | - | - | - | - | - | - | - | - |
| Interest Coverage | -74.61x | -62.48x | -76.99x | -101.75x | -517.56x | -6420.85x | -53.84x | -913.71x | - |
| Total Equity | 125.85M | 25.98M | 113.62M | 189.71M | 263.46M | 363.05M | 429.85M | -276K | 9.15M |
| Equity Growth % | 286.62% | -77.13% | -40.11% | -27.99% | -27.43% | -15.54% | - | -103.01% | - |
| Book Value per Share | 0.89 | 0.48 | 2.18 | 4.41 | 6.47 | 9.01 | 10.79 | -0.01 | 0.42 |
| Total Shareholders' Equity | 125.85M | 25.98M | 113.62M | 189.71M | 263.46M | 363.05M | 429.85M | -276K | 9.15M |
| Common Stock | 143K | 54K | 53K | 50K | 41K | 41K | 40K | 3K | 3K |
| Retained Earnings | -780.54M | -722.82M | -621.12M | -486.27M | -325.47M | -201.99M | -118.52M | -72.78M | -53.54M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -259K | 28K | 275K | 256K | -845K | 0 | 0 | 0 | -1.02M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying ALXO stock.
As of 2025, ALX Oncology Holdings Inc. (ALXO) had total assets of $59.0M including $50.7M in current assets.
ALX Oncology Holdings Inc. (ALXO) carries total debt of $5.2M, offset by $44.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
ALX Oncology Holdings Inc. (ALXO) has total shareholders' equity (book value) of $26.0M ($0.48 book value per share). Book value represents the net worth of the company belonging to common stock holders.
ALX Oncology Holdings Inc. (ALXO) reported a current ratio of 2.07x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Dependence on external capital markets
Metrics are mathematically derived from official filings.
Equity Eroded by Accumulated Losses
According to ALXO's reported balance sheets, total assets swung from $212.7M in 2024Q1 to $160.8M in 2026Q2 while accumulated deficit deepened to $758.7M, indicating a balance sheet being consumed by sustained operating losses over the period.
The reported figures suggest the balance sheet is weakening in aggregate, with the accumulated deficit growing every quarter while asset levels have trended lower. The apparent rebound in assets during 2026Q1 appears linked to a financing inflow rather than operating strength, which warrants further investigation through the cash flow statement. Investors should monitor whether the current cash base supports the program timeline without another raise.
Cash Buffer Thin Against Burn Rate
Based on reported figures, ALXO held $22.7M in cash at 2026Q2 against free cash flow of roughly -$34.8M in the same quarter, suggesting the existing liquidity cushion covers less than one quarter of cash consumption.
The current ratio of 9.71 looks strong on the surface, but it reflects a small liability base rather than a large cash reserve, so the ratio overstates true resilience. Cash of $22.7M against quarterly burn near $35M implies the company likely needs external capital in the near term. The reported figures do not disclose financing commitments, so the adequacy of runway remains an open question for analysts to assess.
Negligible Leverage, Equity-Funded Model
As reported in financial statements, ALXO's total debt fell to $9.7M in 2026Q2 with a debt-to-equity ratio of 0.07, indicating the company is financed almost entirely by equity rather than borrowing.
Low leverage means debt service is not a constraint on cash flow, which is a relative positive given the burn profile. The low debt level instead shifts the risk toward equity dilution, since the business depends on share issuance to fund operations. Investors should treat the balance sheet's apparent lack of leverage as a function of the funding model rather than evidence of financial strength.
Equity Base Dependent on Issuance
Based on ALXO's reported figures, shareholders' equity rose to $136.2M in 2026Q2 from $26.0M in 2025Q4 while retained earnings remained deeply negative, pointing to equity replenishment through capital raises rather than earnings.
The sharp equity increase during 2026 is inconsistent with any earnings contribution, given the persistent accumulated deficit, and suggests dilutive issuance funded the recent asset base. Stock-based compensation further adds to share-count pressure over time. Analysts should evaluate per-share value creation against the continued issuance pattern implied by the reported equity trajectory.
Low Leverage Masks Funding Risk
The headline debt-to-equity ratio of 0.07 may look reassuring, but reported figures suggest the company's real constraint is its reliance on external equity funding to offset a cumulative operating loss exceeding $200M.
A clean debt profile can understate risk when the business has no reported revenue base to service obligations or fund operations internally. The absence of borrowing is a function of the equity-funded model and does not imply durable self-sufficiency. This reading suggests investors should weigh the dilution exposure more heavily than the leverage metrics alone.